Klayon Therapeutics
Zwitterionic peptide-based radiopharmaceutical platform for precise tumor targeting
Klayon Therapeutics develops radiopharmaceuticals using the Z-ION ARK™ platform, a zwitterionic peptide-based technology designed to reduce non-specific binding and improve tumor targeting in oncology. The platform form…
B2B / partnerships / collaborations


